Stockscreener 앱 받기
24.53
4.65%
1.09
시장 영업 전:
24.87
0.34
+1.39%
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts - Seeking Alpha
50,285 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Bought by Avanza Fonder AB - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones - MSN
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones By Investing.com - Investing.com South Africa
Beam Therapeutics (NASDAQ:BEAM) Shares Down 8%Should You Sell? - MarketBeat
Beam Therapeutics’ (BEAM) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Beam Therapeutics (NASDAQ:BEAM) Given Outperform Rating at Wedbush - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Down 8%Time to Sell? - MarketBeat
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? - MSN
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates By Investing.com - Investing.com South Africa
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates - Investing.com India
Beam Therapeutics Announces Progress in Hematology and - GlobeNewswire
Beam Therapeutics Advances Sickle Cell Treatment: 13 Patients Dosed, $850M Cash Position Powers 2025 Pipeline - StockTitan
Catherine Wood's Strategic Reduction in Beam Therapeutics Inc - GuruFocus.com
JPMorgan Chase & Co. Sells 144,127 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy - Schaeffers Research
Beam upgraded by Bernstein ahead of AATD data - MSN
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Trading Up 6.7%Here's What Happened - MarketBeat
Beam upgraded by Bernstein ahead of AATD data (BEAM:NASDAQ) - Seeking Alpha
Beam Therapeutics chief legal officer sells $30,627 in stock By Investing.com - Investing.com Australia
Beam Therapeutics Inc. (NASDAQ:BEAM) Insider Sells $30,627.88 in Stock - MarketBeat
Beam Therapeutics chief legal officer sells $30,627 in stock - Investing.com India
Beam Therapeutics SVP Bethany J Cavanagh sells $27,567 in stock By Investing.com - Investing.com Canada
(BEAM) Technical Pivots with Risk Controls - Stock Traders Daily
Top 5 CRISPR Companies To Invest In (January 2025) - Securities.io
Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Beam Therapeutics Breaks Below 200-Day Moving AverageNotable for BEAM - Nasdaq
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Beam Therapeutics (NASDAQ:BEAM) Trading Down 2.6%Time to Sell? - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $44.30 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
(BEAM) Long Term Investment Analysis - Stock Traders Daily
5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation - Simply Wall St
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Beam Therapeutics CEO to Present at J.P. Morgan Healthcare Conference: Precision Gene Editing Spotlight - StockTitan
State Street Corp Purchases 437,402 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
4.81%
자본화:
|
볼륨(24시간):